BriaCell Therapeutics Corp.’s (OTCQB: BCTXF) (TSX.V: BCT) Breast Cancer Treatment Confirms Positive Anti-Tumor Activity
The safety of a novel combined advanced breast cancer treatment has proven to be excellent, BriaCell announced at a major breast cancer conference The monotherapy (i.e. drug on its own) clinical trial showed positive anti-tumor activity in patients with advanced breast cancer and metastases Further information about the efficiency of the Bria-IMT/KEYTRUDA combined treatment will be provided in the first quarter of 2019 Initial data from a combination study of Bria-IMT and KEYTRUDA (pembrolizumab) demonstrated an excellent safety profile, BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) announced at the 2018 San Antonio Breast Cancer Symposium (http://ibn.fm/ehRA0). During the conference, the…